Drug Trial Radar · NCT06801184
Single-center Exploratory Study of the Intestinal Microbiota in Patients Treated for Irritable Bowel Syndrome With Predominant Constipation and Methane Production
Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Feb 10, 2025
Primary completion
Oct 10, 2028
Study completion Oct 10, 2028
Sponsor
- Lead sponsor
- Hospices Civils de LyonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 30, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Irritable Bowel Syndrome (IBS), characterized by the Rome IV criteria, is a functional bowel disorder combining abdominal pain with changes in bowel habits and/or stool consistency. This condition is common, affecting 5% to 10% of the population in developed countries. The etiology of IBS is multifactorial, involving intestinal motility disorders, visceral hypersensitivity, micro-inflammation of the intestinal mucosa, and dysbiosis. It has been demonstrated that the sub-category of IBS patients with constipation predominantly have increased amounts of Methanobrevibacter smithii, the most common methanogenic archaea found in the intestinal lumen, compared to other IBS patients. Breath tests can evaluate methane production by the intestinal microbiota, indirectly assessing the presence and quantity of methanogenic archaea. The acronym IMO (intestinal methanogen overgrowth) defines the association of digestive symptoms (notably bloating and constipation) with a high concentration of methane in exhaled gases (≥ 10 ppm). The links between constipation, methane production, and fecal microbiota are uncertain, necessitating further studies that could lead to precise diagnostic and treatment recommendations. Main objective: Describe the initial composition of the fecal microbiota of constipated methano-producing IBS patients. Secondary objectives: 2\. Describe the initial composition of blood metabolites linked to the microbiota of constipated methano-producing IBS patients 3. Describe the evolution of the fecal microbiota and blood metabolites linked to the fecal microbiota during conventional therapeutic management (before and after) of constipated methano-producing IBS patients. 4\. Compare the composition of the fecal microbiota before and after conventional therapeutic management of responding IBS-C patients (-30% on the IBS-SSS symptom severity score) compared to non-responding patients. 5\. Evaluate the impact of Methanobrevicter smithii in the response to symptomatic treatment. Exploratory observational single-center study (cohort follow-up) descriptive in patients with irritable bowel syndrome with constipation (IBS-C, IBS-m or IBS-U) with excessive methane production detected on a glucose breath test. Patients will be invited to participate once the results of the breath test are known. Please note: In the context of this study, only two microbiota samples and 4 additional tubes and one tube of blood will be added to the usual practice. All treatments will be prescribed as part of the care and are not conditioned by the research protocol. The primary endpoint is the analysis of the initial composition (16S rRNA gene sequencing) of the fecal microbiota of constipated methano-producing IBS patients. The study population consists of constipated IBS patients with excessive methane production seen in the digestive functional exploration department for a breath test prescribed as part of an external procedure or a day hospital session. A total of 40 patients will be included over 18 months, with a participation duration of 2 months +/- 2months per subject. Patients with IBS constitute a heterogeneous population for whom only symptomatic treatment is currently offered with variable and unpredictable efficacy. Through this work, we seek to find new therapeutic axes to relieve or even treat their symptoms.
Conditions
- Irritable Bowel Syndrome
Interventions
Plasma SampleBiological
A peripheral venous blood sample will be collected on the day of the inclusion consultation and during the follow-up consultation at V2. These samples will be collected in a single2 tubes (4 mL and 5 mL)l tube and will be taken simultaneously with routine blood samples, which require 2 tubes (10 3 mL and 4 mLl).
Stool SampleBiological
Approximately 1 gram of stool will be collected by the patient at home within 72 hours following the inclusion consultation and the follow-up consultation at V2, using the kits provided along with the instructions. The stools will be immediately collected into two tubes: one tube with nucleic acid preservative and one tube conservative to ensure for future metabolomic analyses. The patient will then send the sample using the pre-paid envelope included in the kit to the HCL microbiota biobank (CRB GHN) for aliquoting and storage at -80°C.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Analysis of the initial composition (sequencing of the 16S rRNA gene) of the fecal microbiota in IBS patients with constipation and methane production.Time frame: within 2 months from the first evaluation
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hôpital Edouard Herriot
Lyon, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.